Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

• Published in: Journal of bone and mineral research Vol. 20; no. 10; pp. 1804 - 1812
• Main Authors: Nenonen, Arja, Cheng, Sulin, Ivaska, Kaisa K, Alatalo, Sari L, Lehtimäki, Terho, Schmidt‐Gayk, Heinrich, Uusi‐Rasi, Kirsti, Heinonen, Ari, Kannus, Pekka, Sievänen, Harri, Vuori, Ilkka, Väänänen, H Kalervo, Halleen, Jussi M
• Format: Journal Article
• Language: English
• Published: Washington, DC John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR) 01.10.2005; American Society for Bone and Mineral Research
• Subjects: Acid Phosphatase - blood; alendronate; Alendronate - administration & dosage; Biological and medical sciences; Biomarkers - blood; Bone Density Conservation Agents - administration & dosage; bone markers; Calcium - administration & dosage; Double-Blind Method; Drug Monitoring; Female; Fundamental and applied biological sciences. Psychology; Humans; Isoenzymes - blood; Middle Aged; Osteogenesis - drug effects; Postmenopause - blood; randomized study; Skeleton and joints; Tartrate-Resistant Acid Phosphatase; TRACP 5b; treatment monitoring; Vertebrates: osteoarticular system, musculoskeletal system; Vitamin D - administration & dosage; Diphosphonic acid derivatives; Bisphosphonates; Osteoarticular system; Alendronic acid; Vertebrata; Mammalia; Treatment; Turnover; bone markers; alendronate; Bone; TRACP 5b; treatment monitoring; Monitoring; randomized study
• ISSN: 0884-0431; 1523-4681
• DOI: 10.1359/JBMR.050403

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S‐CTX, U‐DPD, S‐PINP, S‐BALP, and S‐OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal‐to‐noise ratio than the other markers. Introduction: The purpose of this study was to compare the clinical performance of serum TRACP 5b (S‐TRACP5b) with that of other markers of bone turnover in the monitoring of alendronate treatment. Materials and Methods: This double‐blinded study included 148 healthy postmenopausal women that were randomly assigned into two groups: one receiving 5 mg alendronate daily (n = 75) and the other receiving placebo (n = 73) for 12 months. All individuals in both groups received calcium and vitamin D daily. The bone resorption markers S‐TRACP5b, serum C‐terminal cross‐linked telopeptides of type I collagen (S‐CTX), and total urinary deoxypyridinoline (U‐DPD), and the serum markers of bone formation procollagen I N‐terminal propeptide (S‐PINP), bone‐specific alkaline phosphatase (S‐BALP), and total osteocalcin (S‐OC) were assessed at baseline and at 3, 6, and 12 months after initiation of treatment. Lumbar spine BMD (LBMD) was measured at baseline and 12 months. Results: Compared with the placebo group, LBMD increased, and all bone markers decreased significantly more in the alendronate group (p < 0.001 for each parameter). The decrease of S‐TRACP5b after first 3 months of alendronate treatment correlated significantly with the changes of all other markers except S‐OC, the best correlation being with S‐CTX (r = 0.60, p < 0.0001). The changes of LBMD at 12 months only correlated significantly with the changes of S‐TRACP5b (r = −0.32, p = 0.005) and S‐CTX (r = −0.24, p = 0.037) at 3 months. Based on clinical sensitivity, receiver operating characteristic (ROC) curves, and signal‐to‐noise ratio, S‐TRACP5b, S‐CTX, and S‐PINP were the best markers for monitoring alendronate treatment. Clinical sensitivity, area under the ROC curve, and signal‐to‐noise ratio were higher for S‐TRACP5b than for the other markers. Conclusion: These results show that S‐TRACP5b, S‐CTX, and S‐PINP are useful markers for monitoring alendronate treatment.